Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

Rohit Gupta, BA, Jason H. Rogers, MS, Xin Long, PhD, Geraldo Medrano, BS, Jaime M. Reyes, BS, Michele Redell, MD PhD, Zachary T Ball, PhD, Margaret Goodell, PhD, Rachel E. Rau, MD

Blood (2019) 134 (Supplement_1): 3789.

https://doi.org/10.1182/blood-2019-127209

Published: 2019

Journal Articles

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

Aurélie Cabannes, MD, Aline Schmidt, MD, Eolia Brissot, MD PhD, Marie Balsat, MD, Sébastien Maury, MD PhD, Francoise Isnard, MD PhD, Patrice Chevallier, MD, Victoria Cacheux, Thomas Cluzeau, MD PhD, Carlos Graux, Ludovic Lhermitte, MD PhD, Herve Dombret, MD PhD, Nicolas Boissel, MD PhD, Vahid Asnafi, MD PhD, Philippe Rousselot, MD PhD

Blood (2019) 134 (Supplement_1): 1339.

https://doi.org/10.1182/blood-2019-130818

Published: 2019

Journal Articles

Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background

Mianmian Yin, Yang Jo Chung, R. Coleman Lindsley, Robert L. Walker, Yuelin J. Zhu, Benjamin L. Ebert, Paul S. Meltzer, Peter D. Aplan

Blood (2019) 133 (24): 2610–2614.

https://doi.org/10.1182/blood.2018864173

Published: 2019

Journal Articles

Engineered Bcor Mutations Lead to Acute Lymphoblastic Leukemia of Progenitor B-1 Lymphocyte Origin in a Sensitized Background

Mianmian Yin, PhD, Yang Jo Chung, PhD, R. Coleman Lindsley, MD, PhD, Yeulin Zhu, PhD, Robert L. Walker, PhD, Benjamin L. Ebert, MDPhD, Paul S. Meltzer, MD PhD, Peter D. Aplan, MD

Blood (2018) 132 (Supplement 1): 1331.

https://doi.org/10.1182/blood-2018-99-115388

Published: 2018

Journal Articles

Critical Role of Jumonji Domain of JMJD1C in AML Leukemogenesis

Jesus Izaguirre-Carbonell, PhD, Christiansen Luke, Robert Burns, PhD, Jesse Schmitz, Chenxuan Li, Rebekah Mokry, Theresa Bluemn, Yongwei Zheng, Demin Wang, PhD, Nan Zhu, PhD

Blood (2018) 132 (Supplement 1): 2599.

https://doi.org/10.1182/blood-2018-99-110463

Published: 2018

Journal Articles

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

Sigrid Dubois, PhD, Milos D. Miljkovic, MD, Thomas Fleisher, Jennifer Hsu, RN, Thomas A Waldmann, MD, Kevin C Conlon, MD

Blood (2017) 130 (Supplement 1): 3840.

https://doi.org/10.1182/blood.V130.Suppl_1.3840.3840

Published: 2017

Journal Articles

JAK3 Variants in Adults with Myeloid Malignancies and Potential for Response to JAK3 Inhibition

Rita Assi, MD, Christopher B Benton, MD, Ahmed Al Rawi, Kamal Chamoun, MD, Feng Wang, PhD, Sherry Pierce, BSN, BA, Keyur P. Patel, MBBS, PhD, Betty K. Hamilton, MD, Courtney D. DiNardo, MDMSc, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Tapan Kadia, MD, Srdan Verstovsek, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 1381.

https://doi.org/10.1182/blood.V130.Suppl_1.1381.1381

Published: 2017

Journal Articles

PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma

Sung Hee Kil, PhD, Renee Estephan, BS, James Sanchez, PhD, Jasmine M. Zain, MD, Marshall E. Kadin, MD, James W. Young, MD, Steven T. Rosen, MD, Christiane Querfeld, MD PhD

Blood (2017) 130 (Supplement 1): 1458.

https://doi.org/10.1182/blood.V130.Suppl_1.1458.1458

Published: 2017

Journal Articles

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Nathalie Meurice, PhD, Joachim L Petit, PhD, Cecilia Bonolo De Campos, PhD, Alysia N Polito, BS, Ilsel D Lopez Armenta, BS, Gregory J Ahmann, BS, Laura Ann Bruins, BS, Joseph R Mikhael, MD FRCPC, MD, Craig B. Reeder, MD, Angela A Mayo, MS, PA-C, P. Leif Bergsagel, MD, Rafael Fonseca, MD, Nikolai Sepetov, PhD, Sergei Romanov, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 3080.

https://doi.org/10.1182/blood.V130.Suppl_1.3080.3080

Published: 2017

Journal Articles

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Matthew D Blunt, PhD, Rachel Dobson, BSc(Hons), Lindsay D Smith, PhD, Jonathan C. Strefford, Pamela B. Conley, PhD, Anjali Pandey, PhD, Andrew J Davies, FRCP PhD, Peter M Johnson, MA, MD, Graham Packham, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Greg P Coffey, PhD, Andrew J Steele, PhD

Blood (2016) 128 (22): 351.

https://doi.org/10.1182/blood.V128.22.351.351

Published: 2016

Journal Articles

Tofacitinib Reverses Growth Promoting Effects of the Bone Marrow Stromal Environment Though Inhibition of JAK1/STAT3 Signaling in Multiple Myeloma

Christine Lam, Megan Murnane, M.Sc., Geoffrey A. Smith, Jack Taunton, PhD, Blake T. Aftab, PhD, Arun P. Wiita, MD PhD

Blood (2016) 128 (22): 2098.

https://doi.org/10.1182/blood.V128.22.2098.2098

Published: 2016

Journal Articles

Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia

Koshi Akahane, MD PhD, Zhaodong Li, PhD, Julia Etchin, PhD, Alla Berezovskaya, Evisa Gjini, PhD, Craig E Masse, PhD, Wenyan Miao, PhD, Jennifer Rocnik, PhD, Rosana Kapeller, MD PhD, Jeremy R Greenwood, PhD, Hong Tiv, Takaomi Sanda, MD PhD, David M Weinstock, MD, A. Thomas Look, MD

Blood (2016) 128 (22): 1596.

https://doi.org/10.1182/blood.V128.22.1596.1596

Published: 2016

Journal Articles

The Impact of Chemotherapeutic Agents on Signaling and Epigenetics in Vascular Endothelial Cells

Srila Gopal, MD, Amanda Creech, Adam Officer, Shawn Egri, Desiree Davison, Jacob D Jaffe, PhD, Iris Z Jaffe, MD PhD

Blood (2016) 128 (22): 1353.

https://doi.org/10.1182/blood.V128.22.1353.1353

Published: 2016

Journal Articles

Regulation of T-Cell Activation and Differentiation

Golnaz Vahedi, PhD

Blood (2016) 128 (22): SCI-11.

https://doi.org/10.1182/blood.V128.22.SCI-11.SCI-11

Published: 2016

Journal Articles

Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib

Mike Wei, B.S., Nebu Koshy, MD, Koen van Besien, MD, Giorgio Inghirami, MD, Steven M. Horwitz, MD

Blood (2015) 126 (23): 5486.

https://doi.org/10.1182/blood.V126.23.5486.5486

Published: 2015

Journal Articles

Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia

Srinivasa Reddy Sanikommu, MD, Michael Clemente, MS, Peter Chomczynski, Swapna Thota, MD, Bhumika J. Patel, Aziz Nazha, MD, Bartlomiej Przychodzen, MSc, Jaroslaw P Maciejewski, MD PhD FACP

Blood (2015) 126 (23): 2216.

https://doi.org/10.1182/blood.V126.23.2216.2216

Published: 2015

Journal Articles

A Novel, Oncogenic CSF2RB Mutation Found in a Primary Leukemia Sample Results in Constitutive Signaling, Increased Receptor Stability, and Formation of Intermolecular Complexes

Kevin M Watanabe-Smith, BS, Cristina E. Tognon, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Anupriya Agarwal, PhD

Blood (2015) 126 (23): 3670.

https://doi.org/10.1182/blood.V126.23.3670.3670

Published: 2015

Journal Articles

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Megan Murnane, M.Sc., Eugen Dhimolea, PhD, Ruojing Li, BS, Megan A. Bariteau, BSc, Diamond D. Wheeler, BS, Rosemary J. Akhurst, PhD, Aaron C. Logan, MD PhD, Pamela Munster, MD, Arun Wiita, MD PhD, Thomas G. Martin, III, MD, Jeffrey L. Wolf, MD PhD, Jun O. Liu, PhD, Constantine S. Mitsiades, MD PhD, Blake T. Aftab, PhD

Blood (2015) 126 (23): 503.

https://doi.org/10.1182/blood.V126.23.503.503

Published: 2015

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

Jarno Kivioja, MSc, Mika Kontro, MD, Angeliki Thanasopoulou, PhD, Muntasir Mamun Majumder, MSc,BPharm, Bhagwan Yadav, MSc, Heikki Kuusanmäki, MSc, Alun Parsons, MSc, Juerg Schwaller, MD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2014) 124 (21): 2160.

https://doi.org/10.1182/blood.V124.21.2160.2160

Published: 2014

NARROW

Targeting Activated Signaling Pathways for the Treatment of IKZF1 -Deleted B Lymphoblastic Leukemia

The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL)

Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background

Engineered Bcor Mutations Lead to Acute Lymphoblastic Leukemia of Progenitor B-1 Lymphocyte Origin in a Sensitized Background

Critical Role of Jumonji Domain of JMJD1C in AML Leukemogenesis

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

JAK3 Variants in Adults with Myeloid Malignancies and Potential for Response to JAK3 Inhibition

PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Tofacitinib Reverses Growth Promoting Effects of the Bone Marrow Stromal Environment Though Inhibition of JAK1/STAT3 Signaling in Multiple Myeloma

Anti-Leukemic Activity of the TYK2 Selective Inhibitor Ndi-031301 in T-Cell Acute Lymphoblastic Leukemia

The Impact of Chemotherapeutic Agents on Signaling and Epigenetics in Vascular Endothelial Cells

Regulation of T-Cell Activation and Differentiation

Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib

Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia

A Novel, Oncogenic CSF2RB Mutation Found in a Primary Leukemia Sample Results in Constitutive Signaling, Increased Receptor Stability, and Formation of Intermolecular Complexes

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only